InSite Shares Gain on BromSite Phase III Data
By Marie Powers
Tuesday, March 19, 2013
Investors took notice as InSite Vision Inc. reported positive top-line findings from its first Phase III trial of BromSite (ISV-303) for the reduction of inflammation and pain following cataract surgery. The company said BromSite, which combines a low dose (0.075 percent) of the nonsteroidal anti-inflammatory (NSAID) bromfenac with InSite's DuraSite drug delivery technology, achieved statistically significant superiority compared to vehicle.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.